Skip to main content

Table 4 Association of the baseline immune-response profiles with the clinical outcomes of initial therapy at 21 to 24 weeks of follow up in 71 patients with RA

From: Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity

  ΔDAS28 ΔHAQ-DI
Profile Model r P r P
CMV/EBV-1 Unadjusted 0.28b 0.03b -0.05 0.65
  Adjusteda 0.38b 0.007b 0.08 0.59
CMV/EBV-2 Unadjusted -0.01 0.94 -0.18 0.13
  Adjusteda 0.04 0.79 -0.13 0.36
PHA-1 Unadjusted 0.03 0.81 0.03 0.80
  Adjusteda 0.02 0.91 -0.01 0.93
PHA-2 Unadjusted 0.16 0.23 0.10 0.42
  Adjusteda 0.13 0.40 0.09 0.56
Media-1 Unadjusted 0.22 0.09 0.10 0.41
  Adjusteda 0.27 0.064 0.19 0.20
Media-2 Unadjusted 0.26b 0.04b 0.12 0.33
  Adjusteda 0.31b 0.034b 0.19 0.20
  1. Shown are the Spearman correlations between the PCA stimulus-cytokine scores for the first and second principal components and both the change in the DAS28 and the change in the HAQ disability index from baseline to 21 to 24 weeks. aAdjusted for age, sex, body mass index, smoking status, RF status, ACPA status, CMV IgG status, methotrexate use, and prednisone use; bvalues are statistically significant. DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire disability index; CMV/EBV, cytomegalovirus/Epstein-Barr virus; PHA, phytohemagglutinin; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies.